Cargando…
A new algorithm to convert a normal antibody into the corresponding catalytic antibody
Over thousands of monoclonal antibodies (mAbs) have been produced so far, and it would be valuable if these mAbs could be directly converted into catalytic antibodies. We have designed a system to realize the above concept by deleting Pro(95), a highly conserved residue in CDR-3 of the antibody ligh...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096177/ https://www.ncbi.nlm.nih.gov/pubmed/32232151 http://dx.doi.org/10.1126/sciadv.aay6441 |
_version_ | 1783510764212977664 |
---|---|
author | Hifumi, Emi Taguchi, Hiroaki Tsuda, Haruna Minagawa, Tetsuro Nonaka, Tamami Uda, Taizo |
author_facet | Hifumi, Emi Taguchi, Hiroaki Tsuda, Haruna Minagawa, Tetsuro Nonaka, Tamami Uda, Taizo |
author_sort | Hifumi, Emi |
collection | PubMed |
description | Over thousands of monoclonal antibodies (mAbs) have been produced so far, and it would be valuable if these mAbs could be directly converted into catalytic antibodies. We have designed a system to realize the above concept by deleting Pro(95), a highly conserved residue in CDR-3 of the antibody light chain. The deletion of Pro(95) is a key contributor to catalytic function of the light chain. The S35 and S38 light chains have identical amino acid sequences except for Pro(95). The former, with Pro(95) did not show any catalytic activity, whereas the latter, without Pro(95), exhibited peptidase activity. To verify the generality of this finding, we tested another light chain, T99wt, which had Pro(95) and showed little catalytic activity. In contrast, a Pro(95)-deleted mutant enzymatically degraded the peptide substrate and amyloid-beta molecule. These two cases demonstrate the potential for a new method of creating catalytic antibodies from the corresponding mAbs. |
format | Online Article Text |
id | pubmed-7096177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-70961772020-03-30 A new algorithm to convert a normal antibody into the corresponding catalytic antibody Hifumi, Emi Taguchi, Hiroaki Tsuda, Haruna Minagawa, Tetsuro Nonaka, Tamami Uda, Taizo Sci Adv Research Articles Over thousands of monoclonal antibodies (mAbs) have been produced so far, and it would be valuable if these mAbs could be directly converted into catalytic antibodies. We have designed a system to realize the above concept by deleting Pro(95), a highly conserved residue in CDR-3 of the antibody light chain. The deletion of Pro(95) is a key contributor to catalytic function of the light chain. The S35 and S38 light chains have identical amino acid sequences except for Pro(95). The former, with Pro(95) did not show any catalytic activity, whereas the latter, without Pro(95), exhibited peptidase activity. To verify the generality of this finding, we tested another light chain, T99wt, which had Pro(95) and showed little catalytic activity. In contrast, a Pro(95)-deleted mutant enzymatically degraded the peptide substrate and amyloid-beta molecule. These two cases demonstrate the potential for a new method of creating catalytic antibodies from the corresponding mAbs. American Association for the Advancement of Science 2020-03-25 /pmc/articles/PMC7096177/ /pubmed/32232151 http://dx.doi.org/10.1126/sciadv.aay6441 Text en Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (http://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Research Articles Hifumi, Emi Taguchi, Hiroaki Tsuda, Haruna Minagawa, Tetsuro Nonaka, Tamami Uda, Taizo A new algorithm to convert a normal antibody into the corresponding catalytic antibody |
title | A new algorithm to convert a normal antibody into the corresponding catalytic antibody |
title_full | A new algorithm to convert a normal antibody into the corresponding catalytic antibody |
title_fullStr | A new algorithm to convert a normal antibody into the corresponding catalytic antibody |
title_full_unstemmed | A new algorithm to convert a normal antibody into the corresponding catalytic antibody |
title_short | A new algorithm to convert a normal antibody into the corresponding catalytic antibody |
title_sort | new algorithm to convert a normal antibody into the corresponding catalytic antibody |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096177/ https://www.ncbi.nlm.nih.gov/pubmed/32232151 http://dx.doi.org/10.1126/sciadv.aay6441 |
work_keys_str_mv | AT hifumiemi anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody AT taguchihiroaki anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody AT tsudaharuna anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody AT minagawatetsuro anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody AT nonakatamami anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody AT udataizo anewalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody AT hifumiemi newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody AT taguchihiroaki newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody AT tsudaharuna newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody AT minagawatetsuro newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody AT nonakatamami newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody AT udataizo newalgorithmtoconvertanormalantibodyintothecorrespondingcatalyticantibody |